Departments of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hubertus Wald Cancer Center, Hamburg, Germany.
Acta Haematol. 2012;128(2):69-72. doi: 10.1159/000338179. Epub 2012 Jun 6.
Macrophage activation syndrome (MAS) is a life-threatening disease with sustained activation of inflammatory cells and release of proinflammatory TNF-α. Under physiological conditions, TNF-α initiates a negative feedback mechanism, mediated by shedded, soluble TNF receptor ectodomains, eventually limiting the inflammatory reaction. Here, we report on a 27-year-old critically ill patient with refractory MAS and an insufficient negative feedback regulation, resulting in an overwhelming inflammatory response. A personalized treatment with soluble TNF receptor etanercept resulted in a durable remission. Further studies are warranted to establish whether the TNF cytokine profile may help to successfully guide patient selection for biological therapies.
巨噬细胞活化综合征(MAS)是一种危及生命的疾病,其特征为炎症细胞持续活化和促炎细胞因子 TNF-α 的释放。在生理条件下,TNF-α 通过脱落的、可溶性 TNF 受体胞外结构域介导负反馈机制,最终限制炎症反应。在此,我们报告了一例 27 岁的重症 MAS 患者,其负反馈调节不足,导致炎症反应失控。采用可溶性 TNF 受体依那西普进行个体化治疗,获得了持久缓解。进一步的研究是必要的,以确定 TNF 细胞因子谱是否有助于成功指导生物治疗的患者选择。